Your browser doesn't support javascript.
loading
A scalable system for generation of mesenchymal stem cells derived from induced pluripotent cells employing bioreactors and degradable microcarriers.
Rogers, Robert E; Haskell, Andrew; White, Berkley P; Dalal, Sujata; Lopez, Megan; Tahan, Daniel; Pan, Simin; Kaur, Gagandeep; Kim, Hyemee; Barreda, Heather; Woodard, Susan L; Benavides, Oscar R; Dai, Jing; Zhao, Qingguo; Maitland, Kristen C; Han, Arum; Nikolov, Zivko L; Liu, Fei; Lee, Ryang Hwa; Gregory, Carl A; Kaunas, Roland.
Afiliação
  • Rogers RE; Department of Molecular and Cellular Medicine, Texas A&M Health Science Center, College of Medicine, Bryan, Texas, USA.
  • Haskell A; Department of Molecular and Cellular Medicine, Texas A&M Health Science Center, College of Medicine, Bryan, Texas, USA.
  • White BP; Department of Biomedical Engineering, Texas A&M University, Emerging Technologies Building, College Station, Texas, USA.
  • Dalal S; Department of Molecular and Cellular Medicine, Texas A&M Health Science Center, College of Medicine, Bryan, Texas, USA.
  • Lopez M; Department of Molecular and Cellular Medicine, Texas A&M Health Science Center, College of Medicine, Bryan, Texas, USA.
  • Tahan D; Department of Molecular and Cellular Medicine, Texas A&M Health Science Center, College of Medicine, Bryan, Texas, USA.
  • Pan S; Department of Molecular and Cellular Medicine, Texas A&M Health Science Center, College of Medicine, Bryan, Texas, USA.
  • Kaur G; Department of Molecular and Cellular Medicine, Texas A&M Health Science Center, College of Medicine, Bryan, Texas, USA.
  • Kim H; Department of Molecular and Cellular Medicine, Texas A&M Health Science Center, College of Medicine, Bryan, Texas, USA.
  • Barreda H; Department of Molecular and Cellular Medicine, Texas A&M Health Science Center, College of Medicine, Bryan, Texas, USA.
  • Woodard SL; National Center for Therapeutics Manufacturing, Texas A&M University, College Station, Texas, USA.
  • Benavides OR; Department of Biomedical Engineering, Texas A&M University, Emerging Technologies Building, College Station, Texas, USA.
  • Dai J; Department of Electrical and Computer Engineering, Texas A&M University, Wisenbaker Engineering Building, College Station, Texas, USA.
  • Zhao Q; Department of Molecular and Cellular Medicine, Texas A&M Health Science Center, College of Medicine, Bryan, Texas, USA.
  • Maitland KC; Department of Biomedical Engineering, Texas A&M University, Emerging Technologies Building, College Station, Texas, USA.
  • Han A; Department of Biomedical Engineering, Texas A&M University, Emerging Technologies Building, College Station, Texas, USA.
  • Nikolov ZL; Department of Electrical and Computer Engineering, Texas A&M University, Wisenbaker Engineering Building, College Station, Texas, USA.
  • Liu F; National Center for Therapeutics Manufacturing, Texas A&M University, College Station, Texas, USA.
  • Lee RH; Biological and Agricultural Engineering, Texas A&M University, Scoates Hall, College Station, Texas, USA.
  • Gregory CA; Department of Molecular and Cellular Medicine, Texas A&M Health Science Center, College of Medicine, Bryan, Texas, USA.
  • Kaunas R; Department of Molecular and Cellular Medicine, Texas A&M Health Science Center, College of Medicine, Bryan, Texas, USA.
Stem Cells Transl Med ; 10(12): 1650-1665, 2021 12.
Article em En | MEDLINE | ID: mdl-34505405
ABSTRACT
Human mesenchymal stem cells (hMSCs) are effective in treating disorders resulting from an inflammatory or heightened immune response. The hMSCs derived from induced pluripotent stem cells (ihMSCs) share the characteristics of tissue derived hMSCs but lack challenges associated with limited tissue sources and donor variation. To meet the expected future demand for ihMSCs, there is a need to develop scalable methods for their production at clinical yields while retaining immunomodulatory efficacy. Herein, we describe a platform for the scalable expansion and rapid harvest of ihMSCs with robust immunomodulatory activity using degradable gelatin methacryloyl (GelMA) microcarriers. GelMA microcarriers were rapidly and reproducibly fabricated using a custom microfluidic step emulsification device at relatively low cost. Using vertical wheel bioreactors, 8.8 to 16.3-fold expansion of ihMSCs was achieved over 8 days. Complete recovery by 5-minute digestion of the microcarriers with standard cell dissociation reagents resulted in >95% viability. The ihMSCs matched or exceeded immunomodulatory potential in vitro when compared with ihMSCs expanded on monolayers. This is the first description of a robust, scalable, and cost-effective method for generation of immunomodulatory ihMSCs, representing a significant contribution to their translational potential.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Células-Tronco Pluripotentes Induzidas / Células-Tronco Mesenquimais Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Células-Tronco Pluripotentes Induzidas / Células-Tronco Mesenquimais Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article